The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

The FDA has granted orphan drug designation (ODD) to Zai Lab’s ZL-1310, aimed at treating small cell lung cancer (SCLC).

In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent Norwegian ...

Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...

Zai Lab (ZLAB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Li from Bank of ...

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders ...

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Zai Lab in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of ...

NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. Zai Lab shares are trading higher by 4% during ...